Arch Therapeutics, Inc. (ARTH) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
235 WALNUT STREET, SUITE 6 FRAMINGHAM, MA 01702 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| Industry (SIC) | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2023 Q1 | 9/30/2023 Q4 | 6/30/2023 Q3 | 3/31/2023 Q2 | 12/31/2022 Q1 | 9/30/2022 Q4 | 6/30/2022 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 223 | 87 | 29 | 11 | 747 | 55 | |||
| Cash and cash equivalents | 223 | 87 | 29 | 11 | 747 | 55 | |||
| Inventory, net of allowances, customer advances and progress billings | 1,365 | 1,383 | 1,402 | 1,412 | 1,415 | 1,428 | |||
| Inventory | 1,365 | 1,383 | 1,402 | 1,412 | 1,415 | 1,428 | |||
| Other undisclosed current assets | 363 | 91 | 156 | 289 | 436 | 83 | |||
| Total current assets: | 1,950 | 1,560 | 1,588 | 1,711 | 2,598 | 1,567 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 5 | 1 | 1 | 1 | 2 | 3 | |||
| Other noncurrent assets | 4 | 4 | 4 | 4 | 4 | 4 | |||
| Total noncurrent assets: | 8 | 4 | 5 | 5 | 6 | 6 | |||
| TOTAL ASSETS: | 1,958 | 1,564 | 1,593 | 1,716 | 2,604 | 1,573 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 3,127 | 3,292 | 3,072 | 2,000 | 1,584 | 1,696 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | ✕ | 128 | ✕ | ||
| Accounts payable | 2,304 | 2,471 | 2,426 | 1,761 | 1,328 | 1,696 | |||
| Accrued liabilities | 823 | 821 | 646 | 238 | 128 | ||||
| Debt | 690 | 550 | |||||||
| Derivative instruments and hedges, liabilities | 748 | 748 | |||||||
| Other undisclosed current liabilities | 6,339 | 5,598 | 4,907 | 1,397 | 439 | 223 | |||
| Total current liabilities: | 9,466 | 9,579 | 7,979 | 4,145 | 3,320 | 1,919 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 459 | 459 | 1,207 | ||||||
| Derivative instruments and hedges, liabilities | 459 | 459 | 1,207 | ||||||
| Other undisclosed noncurrent liabilities | 3,001 | 3,017 | 2,462 | ||||||
| Total noncurrent liabilities: | 3,460 | 3,476 | 3,669 | ||||||
| Total liabilities: | 9,466 | 9,579 | 7,979 | 7,605 | 6,797 | 5,589 | |||
| Equity | |||||||||
| Equity, attributable to parent | (7,508) | (8,015) | (6,386) | (5,889) | (4,193) | (4,015) | |||
| Common stock | 5 | 1 | 1 | 1 | 250 | 237 | |||
| Additional paid in capital | 54,543 | 51,582 | 51,388 | 50,983 | 50,630 | 48,932 | |||
| Accumulated deficit | (62,056) | (59,598) | (57,775) | (56,873) | (55,073) | (53,184) | |||
| Total equity: | (7,508) | (8,015) | (6,386) | (5,889) | (4,193) | (4,015) | |||
| TOTAL LIABILITIES AND EQUITY: | 1,958 | 1,564 | 1,593 | 1,716 | 2,604 | 1,573 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 12/31/2023 Q1 | 9/30/2023 Q4 | 6/30/2023 Q3 | 3/31/2023 Q2 | 12/31/2022 Q1 | 9/30/2022 Q4 | 6/30/2022 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 40 | 13 | 17 | 6 | 2 | 6 | ||
| Gain on disposition of assets for financial service operations | 1,158 | |||||||
| Cost of revenue | (23) | (19) | (19) | (18) | (0) | (17) | ||
| Gross profit: | 16 | (5) | (2) | (11) | 1 | (11) | ||
| Operating expenses | (1,345) | (1,009) | (1,423) | (1,264) | (1,443) | (996) | ||
| Operating loss: | (1,329) | (1,014) | (1,425) | (1,276) | (1,441) | (1,007) | ||
| Nonoperating income (expense) | (1,128) | (809) | 523 | (524) | (447) | (40) | ||
| Interest and debt expense | (1,128) | (809) | (635) | (524) | (447) | (40) | ||
| Loss from continuing operations: | (3,585) | (2,632) | (1,538) | (2,324) | (2,336) | (1,087) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | ✕ | (2,336) | (1,087) | |
| Net loss: | (3,585) | (2,632) | (1,538) | (2,324) | (2,336) | (1,087) | ||
| Other undisclosed net income attributable to parent | 1,128 | 809 | 635 | 524 | 447 | 40 | ||
| Net loss available to common stockholders, diluted: | (2,457) | (1,823) | (902) | (1,800) | (1,889) | (1,047) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2023 Q1 | 9/30/2023 Q4 | 6/30/2023 Q3 | 3/31/2023 Q2 | 12/31/2022 Q1 | 9/30/2022 Q4 | 6/30/2022 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (3,585) | (2,632) | (1,538) | (2,324) | (2,336) | (1,087) | ||
| Comprehensive loss, net of tax, attributable to parent: | (3,585) | (2,632) | (1,538) | (2,324) | (2,336) | (1,087) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.